Background: In order to establish the clinical breakpoint (CBP) of danofloxacin against G. parasuis, three cutoff values, including epidemiological cutoff value (ECV), pharmacokinetic-pharmacodynamic (PK-PD) cutoff value (COPD) and clinical cutoff value (COCL), were obtained in the present study. Methods: The ECV was calculated using ECOFFinder base on the MIC distribution of danfloxacin against 347 G. parasuis collected from disease pigs. The COPD was established based on in vivo and ex vivo PK-PD modeling of danofloxacin both in plasma and pulmonary epithelial lining fluid (PELF) using Hill formula and Monte Carlo analysis. The COCL was established based on the relationship between the possibility of cure (POC) and MIC in the clinical trials using the “WindoW” approach, nonlinear regression and CART analysis. Results: The MIC50 and MIC90 of danofloxacin against 347 G. parasuis were 2 μg/mL and 8 μg/mL, respectively. The ECV value was set to 8 μg/mL using ECOFFinder. Concentration-time curves of danofloxacin were fitted with a two-compartment PK model. The PK parameters of the maximum concentration (Cmax) and area under concentration-time curves (AUC) in PELF were 3.67 ± 0.25 μg/mL and 24.28 ± 2.70 h·μg/mL, higher than those in plasma (0.67 ± 0.01 μg/mL and 4.47 ± 0.51 h·μg/mL). The peak time (Tmax) in plasma was 0.23 ± 0.07 h, shorter than that in PELF (1.61 ± 0.15 h). The COPD in plasma and PELF were 0.125 μg/mL and 0.5 μg/mL, respectively. The COCL calculated by WindoW approach, nonlinear regression and CART analysis were 0.125–4 μg/mL, 0.428 μg/mL and 0.56 μg/mL, respectively. The 0.5 μg/mL was selected as eligible COCL. The ECV is much higher than the COPD and COCL, and the clinical breakpoint based on data in plasma was largely different from that of PELF. Conclusions: Our study firstly established three cutoff values of danofloxacin against G. parasuis. It suggested that non-wild-type danofloxacin-resistant G. parasuis may lead to ineffective treatment by danofloxacin.
Introduction: Glaesserella parasuis causes Glässer’s disease in pigs, a leading cause of death in swine herds and a major contributor to economic losses in the global swine industry. Although several studies have investigated antimicrobial resistance in G. parasuis, the correlation between phenotypic and genotypic resistance remains unclear due to incomplete genetic resistance mechanisms detection.Methods: The susceptibility of 117 clinical G. parasuis isolates to 7 antimicrobials was determined using a broth microdilution method. The sequences of 48 resistant isolates were obtained by whole-genome sequencing. Resistance genes, mutations, and group 1 vtaAs were detected based on whole-genome sequence data. Sequence types (STs) were identified by multilocus sequence typing (MLST).Results: Phenotypic analysis showed that most isolates were susceptible to the tested antibiotics; resistance was most common against tetracycline (27%) and enrofloxacin (20%). All isolates were susceptible to ceftiofur. Analysis of whole-genome sequences revealed that resistance to tetracycline, amoxicillin, erythromycin, florfenicol, and chloramphenicol was frequently associated with the resistance genes tet(B) or tet(H), blaROB–1, erm(T), floR, and catA3, and enrofloxacin resistance was associated with mutations in GyrA, ParC, and ParE. MLST identified 25 STs, of which, 14 were novel. The sequenced strains were divided into two primary lineages, LI and LII. Group 1 vtaA genes were detected in 87.5% (n = 42) of the isolates.Conclusion: This study provides comprehensive insights into the molecular mechanisms responsible for drug resistance in G. parasuis, the characteristics of molecular epidemiology, and the virulence of resistant groups. Our findings can aid in the development of G. parasuis-specific clinical breakpoints and inform strategies for managing antimicrobial resistance in swine herds.
Glaesserella parasuis is the etiological agent of Glässer’s disease, which causes high morbidity and mortality in pigs worldwide. Macrolide resistance poses an urgent threat to their treatment, as macrolides are widely used for preventing and treating G. parasuis infections. Here, we determined the susceptibilities to five macrolides and characterized the genetic markers of macrolide resistance. The antimicrobial susceptibility of 117 G. parasuis isolates to erythromycin, tulathromycin, gamithromycin, tylosin, and tilmicosin was evaluated using broth microdilution method. Erythromycin-resistant isolates were sequenced using whole-genome sequencing. Further analysis of these sequences revealed the genetic basis of macrolide resistance in G. parasuis. Our results show that most G. parasuis isolates remained susceptible to the macrolide drugs. For commonly used agents (e.g., tylosin and tilmicosin), elevated minimum inhibitory concentrations (MICs) were observed, whereas for the newer macrolides (e.g., tulathromycin and gamithromycin), the MICs remained almost unchanged. The macrolide resistance gene erm(T) and the A2059G mutation in 23S rRNA were detected in the current study. To the best of our knowledge, integrative and conjugative element (ICE)-borne erm(T) in G. parasuis is reported for the first time in this study. Taken together, these results provide insights into the susceptibility of G. parasuis to macrolides. The presence of erm(T) on ICEs may facilitate its transfer, reducing the effectiveness of macrolide treatment.